CYP-catalysed cycling of clozapine and clozapine-N-oxide promotes the generation of reactive oxygen species in vitro

References

• Abdel-Wahab BA, Metwally ME. 2015. Clozapine-induced cardiotoxicity: role of oxidative stress, tumour necrosis factor alpha and NF-κβ. Cardiovasc Toxicol. 15(4):355–365. doi: 10.1007/s12012-014-9304-9.
   PubMed Web of Science ®Google Scholar
• Ahangari R, Khezri S, Jahedsani A, Bakhshii S, Salimi A. 2022. Ellagic acid alleviates clozapine‑induced oxidative stress and mitochondrial dysfunction in cardiomyocytes. Drug Chem Toxicol. 45(4):1625–1633. doi: 10.1080/01480545.2020.1850758.
   PubMed Web of Science ®Google Scholar
• Alawami M, Wasywich C, Cicovic A, Kenedi C. 2014. A systematic review of clozapine induced cardiomyopathy. Int J Cardiol. 176(2):315–320. doi: 10.1016/j.ijcard.2014.07.103.
   PubMed Web of Science ®Google Scholar
• Arzuk E, Karakuş F, Orhan H. 2021. Bioactivation of clozapine by mitochondria of the murine heart: possible cause of cardiotoxicity. Toxicology. 447:152628. doi: 10.1016/j.tox.2020.152628.
   PubMed Web of Science ®Google Scholar
• Bellissima BL. 2018. Clozapine-associated myocarditis and cardiomyopathy: investigating a metabolic basis of toxicity. Auckland (New Zealand): University of Auckland.
   Google Scholar
• Bellissima BL, Tingle MD, Cicović A, Alawami M, Kenedi C. 2018. A systematic review of clozapine-induced myocarditis. Int J Cardiol. 259:122–129. doi: 10.1016/j.ijcard.2017.12.102.
   PubMed Web of Science ®Google Scholar
• Bellissima BL, Vara A, Helsby N, Garavan F, Tingle MD. 2021. Incidence and investigation of potential risk-factors for clozapine-associated myocarditis and cardiomyopathy in a New Zealand cohort. Psychiatry Res. 299:113873. doi: 10.1016/j.psychres.2021.113873.
   PubMed Web of Science ®Google Scholar
• Bickel MH. 1969. The pharmacology and biochemistry of N-oxides. Pharmacol Rev. 21(4):325–355.
   PubMed Web of Science ®Google Scholar
• Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB. 2005. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit. 27(4):539–543. doi: 10.1097/01.ftd.0000164609.14808.93.
   PubMed Web of Science ®Google Scholar
• Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, Pavek P. 2007. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 35(7):1032–1041. doi: 10.1124/dmd.106.014456.
   PubMed Web of Science ®Google Scholar
• Chang W-H, Lin S-K, Lane H-Y, Wei F-C, Hu W-H, Lam YF, Jann MW. 1998. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 22(5):723–739. doi: 10.1016/S0278-5846(98)00035-9.
   PubMed Web of Science ®Google Scholar
• Chaudhary KR, Batchu SN, Seubert JM. 2009. Cytochrome P450 enzymes and the heart. IUBMB Life. 61(10):954–960. doi: 10.1002/iub.241.
   PubMed Web of Science ®Google Scholar
• Chopra N, de Leon J. 2016. Clozapine-induced myocarditis may be associated with rapid titration: a case report verified with autopsy. Int J Psychiatry Med. 51(1):104–115. doi: 10.1177/0091217415621269.
   PubMed Web of Science ®Google Scholar
• Couchman L, Bowskill SVJ, Handley S, Patel MX, Flanagan RJ. 2013. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994–2010. Early Intervention Psych. 7(2):122–130. doi: 10.1111/j.1751-7893.2012.00374.x.
   PubMed Web of Science ®Google Scholar
• Council for International Organizations of Medical Sciences. 2001. Guidelines for preparing core clinical-safety information on drugs: report of CIOMS Working Groups III and V. 2nd ed. Geneva: CIOMS.
   Google Scholar
• Dain JG, Nicoletti J, Ballard F. 1997. Biotransformation of clozapine in humans. Drug Metab Dispos. 25(5):603–609.
   PubMed Web of Science ®Google Scholar
• Danek PJ, Basińska-Ziobroń A, Wójcikowski J, Daniel WA. 2020. Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4. Pharmacol Rep. 73(1):303–308. doi: 10.1007/s43440-020-00157-4.
   PubMed Web of Science ®Google Scholar
• Daniel WA. 2003. Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. Prog Neuropsychopharmacol Biol Psychiatry. 27(1):65–73. doi: 10.1016/S0278-5846(02)00317-2.
   PubMed Web of Science ®Google Scholar
• Das KC, Muniyappa H, Kundumani-Sridharan V, Subramani J. 2021. Thioredoxin decreases anthracycline cardiotoxicity, but sensitizes cancer cell apoptosis. Cardiovasc Toxicol. 21(2):142–151. doi: 10.1007/s12012-020-09605-2.
   PubMed Web of Science ®Google Scholar
• De Las Cuevas C, Sanz EJ, Rohde C, de Leon J. 2022. Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase. Expert Rev Clin Pharmacol. 15(1):65–78. doi: 10.1080/17512433.2022.2032659.
   PubMed Web of Science ®Google Scholar
• de Leon J, Rhee DW, Kondracke A, Diuguid-Gerber J. 2020. Rapid titration and decreased clozapine clearance may help explain five cases of clozapine-induced myocarditis in a New York hospital. Psychosomatics. 61(1):102–103. doi: 10.1016/j.psym.2019.08.008.
   PubMed Web of Science ®Google Scholar
• DeLozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, Murphy E, Steenbergen C, Zeldin DC, Goldstein JA. 2007. Detection of human CYP2C8, CYP2C9 and CYP2J2 in cardiovascular tissues. Drug Metab Dispos. 35(4):682–688. doi: 10.1124/dmd.106.012823.
   PubMed Web of Science ®Google Scholar
• Dragovic S, Boerma JS, van Bergen L, Vermeulen NPE, Commandeur JNM. 2010. Role of human glutathione s-transferases in the inactivation of reactive metabolites of clozapine. Chem Res Toxicol. 23(9):1467–1476. doi: 10.1021/tx100131f.
   PubMed Web of Science ®Google Scholar
• Dragovic S, Gunness P, Ingelman-Sundberg M, Vermeulen NPE, Commandeur JNM. 2013. Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab Dispos. 41(3):651–658. doi: 10.1124/dmd.112.050484.
   PubMed Web of Science ®Google Scholar
• Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. 1997. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 44(5):439–446. doi: 10.1046/j.1365-2125.1997.t01-1-00605.x.
   PubMed Web of Science ®Google Scholar
• Evangelista EA, Kaspera R, Mokadam NA, Jones JP, Totah RA. 2013. Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes. Drug Metab Dispos. 41(12):2087–2094. doi: 10.1124/dmd.113.053389.
   PubMed Web of Science ®Google Scholar
• Fang J, Coutts RT, McKenna KF, Baker GB. 1998. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 358(5):592–599. doi: 10.1007/PL00005298.
   PubMed Web of Science ®Google Scholar
• Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N. 2016. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 50(5):410–472. doi: 10.1177/0004867416641195.
   PubMed Web of Science ®Google Scholar
• Gardner I, Zahid N, MacCrimmon D, Uetrecht JP. 1998. A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol Pharmacol. 53(6):991–998.
   PubMed Web of Science ®Google Scholar
• Hausner EA, Elmore SA, Yang X. 2019. Overview of the components of cardiac metabolism. Drug Metab Dispos. 47(6):673–688. doi: 10.1124/dmd.119.086611.
   PubMed Web of Science ®Google Scholar
• Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, et al. 2018. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 51(1-02):9–62. doi: 10.1055/s-0043-116492.
   PubMed Web of Science ®Google Scholar
• Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW. 1997. Hepatotoxicity of Clozapine. J Clin Psychopharmacol. 17(4):314–317. doi: 10.1097/00004714-199708000-00012.
   PubMed Web of Science ®Google Scholar
• Jann MW, Grimsley SR, Gray EC, Chang W-H. 1993. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet. 24(2):161–176. doi: 10.2165/00003088-199324020-00005.
   PubMed Web of Science ®Google Scholar
• Jendryka M, Palchaudhuri M, Ursu D, van der Veen B, Liss B, Kätzel D, Nissen W, Pekcec A. 2019. Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice. Sci Rep. 9(1):4522. doi: 10.1038/s41598-019-41088-2.
   PubMedGoogle Scholar
• Kilian JG, Kerr K, Lawrence C, Celermajer DS. 1999. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 354(9193):1841–1845. doi: 10.1016/S0140-6736(99)10385-4.
   PubMed Web of Science ®Google Scholar
• Lally J, Gaughran F, Timms P, Curran SR. 2016. Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. Pharmgenomics Pers Med. 9:117–129. doi: 10.2147/PGPM.S115741.
   PubMed Web of Science ®Google Scholar
• Li L, Gao P, Tang X, Liu Z, Cao M, Luo R, Li X, Wang J, Lin X, Peng C, et al. 2022. CB1R-stabilized NLRP3 inflammasome drives antipsychotics cardiotoxicity. Sig Transduct Target Ther. 7(1):1. doi: 10.1038/s41392-022-01018-7.
   PubMed Web of Science ®Google Scholar
• Maggs JL, Williams D, Pirmohamed M, Park BK. 1995. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther. 275(3):1463–1475.
   PubMed Web of Science ®Google Scholar
• Manu P, Sarpal D, Muir O, Kane JM, Correll CU. 2012. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res. 134(2–3):180–186. doi: 10.1016/j.schres.2011.10.014.
   PubMed Web of Science ®Google Scholar
• Manvich DF, Webster KA, Foster SL, Farrell MS, Ritchie JC, Porter JH, Weinshenker D. 2018. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. Sci Rep. 8(1):1. doi: 10.1038/s41598-018-22116-z.
   PubMedGoogle Scholar
• Medsafe 2015. Clozapine – Close monitoring required. https://www.medsafe.govt.nz/profs/puarticles/June2015/June2015Clozapine.htm.
   Google Scholar
• Merrill D, Dec G, Goff D. 2005. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol. 25(1):32–41. doi: 10.1097/01.jcp.0000150217.51433.9f.
   PubMed Web of Science ®Google Scholar
• Murata R, Watanabe H, Nosaki H, Nishida K, Maeda H, Nishida M, Maruyama T. 2022. Long-acting thioredoxin ameliorates doxorubicin-induced cardiomyopathy via its anti-oxidative and anti-inflammatory action. Pharmaceutics. 14(3):562. doi: 10.3390/pharmaceutics14030562.
   PubMed Web of Science ®Google Scholar
• Nielsen J, Young C, Ifteni P, Kishimoto T, Xiang Y-T, Schulte PFJ, Correll CU, Taylor D. 2016. Worldwide differences in regulations of clozapine use. CNS Drugs. 30(2):149–161. doi: 10.1007/s40263-016-0311-1.
   PubMed Web of Science ®Google Scholar
• Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. 1999. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 285(5431):1276–1279. doi: 10.1126/science.285.5431.1276.
   PubMed Web of Science ®Google Scholar
• Patel RK, Moore AM, Piper S, Sweeney M, Whiskey E, Cole G, Shergill SS, Plymen CM. 2019. Clozapine and cardiotoxicity – A guide for psychiatrists written by cardiologists. Psychiatry Res. 282:112491. doi: 10.1016/j.psychres.2019.112491.
   PubMed Web of Science ®Google Scholar
• Perry PJ, Miller DD, Arndt SV, Cadoret RJ. 1991. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 148(2):231–235. doi: 10.1176/ajp.148.2.231.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. 1995. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther. 272(3):984–990.
   PubMed Web of Science ®Google Scholar
• Raper J, Morrison RD, Daniels JS, Howell L, Bachevalier J, Wichmann T, Galvan A. 2017. Metabolism and distribution of clozapine-N-oxide: implications for nonhuman primate chemogenetics. ACS Chem Neurosci. 8(7):1570–1576. doi: 10.1021/acschemneuro.7b00079.
   PubMed Web of Science ®Google Scholar
• Reeves S, Bertrand J, Obee SJ, Hunter S, Howard R, Flanagan RJ. 2023. A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status. Br J Clin Pharmacol. Advance online publication. doi: 10.1111/bcp.15691.
   Google Scholar
• Ren S, Zeng J, Mei Y, Zhang JZH, Yan SF, Fei J, Chen L. 2013. Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. Drug Metab Dispos. 41(1):60–71. doi: 10.1124/dmd.112.048264.
   PubMed Web of Science ®Google Scholar
• Ronaldson KJ. 2017. Cardiovascular disease in clozapine-treated patients: evidence, mechanisms and management. CNS Drugs. 31(9):777–795. doi: 10.1007/s40263-017-0461-9.
   PubMed Web of Science ®Google Scholar
• Ronaldson KJ, Fitzgerald PB, McNeil JJ. 2015. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand. 132(4):231–240. doi: 10.1111/acps.12416.
   PubMed Web of Science ®Google Scholar
• Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. 2011. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 45(6):458–465. doi: 10.3109/00048674.2011.572852.
   PubMed Web of Science ®Google Scholar
• Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ. 2012. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case–control study. Schizophr Res. 141(2-3):173–178. doi: 10.1016/j.schres.2012.08.018.
   PubMed Web of Science ®Google Scholar
• Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. 2010. Atypical antipsychotic metabolism and excretion. Curr Drug Metab. 11(6):516–525. doi: 10.2174/138920010791636202.
   PubMed Web of Science ®Google Scholar
• Stark A, Scott J. 2012. A review of the use of clozapine levels to guide treatment and determine cause of death. Aust N Z J Psychiatry. 46(9):816–825. doi: 10.1177/0004867412438871.
   PubMed Web of Science ®Google Scholar
• Sultan RS, Olfson M, Correll CU, Duncan EJ. 2017. Evaluating the effect of the changes in FDA guidelines for clozapine monitoring. J Clin Psychiatry. 78(8):e933–e939. doi: 10.4088/JCP.16m11152.
   PubMed Web of Science ®Google Scholar
• Tada Y, Suzuki J-I. 2016. Oxidative stress and myocarditis. Curr Pharm Des. 22(4):450–471. doi: 10.2174/1381612822666151222160559.
   PubMed Web of Science ®Google Scholar
• The Human Protein Atlas. 2019a. Tissue expression of GSTA1. https://www.proteinatlas.org/ENSG00000243955-GSTA1/tissue.
   Google Scholar
• The Human Protein Atlas 2019b. Tissue expression of GSTP1. The Human Protein Atlas. https://www.proteinatlas.org/ENSG00000084207-GSTP1/tissue/heart+muscle.
   Google Scholar
• Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K. 2017. Potential role of patients’ CYP3A-status in clozapine pharmacokinetics. Int J Neuropsychopharmacol. 20(7):529–537. doi: 10.1093/ijnp/pyx019.
   PubMed Web of Science ®Google Scholar
• Tugnait M, Hawes EM, McKay G, Eichelbaum M, Midha KK. 1999. Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem Biol Interact. 118(2):171–189. doi: 10.1016/S0009-2797(99)00006-X.
   PubMed Web of Science ®Google Scholar
• Uetrecht J. 2002. N-oxidation of drugs associated with idiosyncratic drug reactions. Drug Metab Rev. 34(3):651–665. doi: 10.1081/DMR-120005667.
   PubMed Web of Science ®Google Scholar
• Wang B, Wu L, Chen J, Dong L, Chen C, Wen Z, Hu J, Fleming I, Wang DW. 2021. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Sig Transduct Target Ther. 6(1):1. doi: 10.1038/s41392-020-00443-w.
   PubMed Web of Science ®Google Scholar
• Whayne TF, Parinandi N, Maulik N. 2015. Thioredoxins in cardiovascular disease. Can J Physiol Pharmacol. 93(11):903–911. doi: 10.1139/cjpp-2015-0105.
   PubMed Web of Science ®Google Scholar
• Williams DP, O'Donnell CJL, Maggs JL, Leeder JS, Uetrecht J, Pirmohamed M, Park BK. 2003. Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro. Chem Res Toxicol. 16(10):1359–1364. doi: 10.1021/tx034035z.
   PubMed Web of Science ®Google Scholar
• Wu Chou AI, Lu M-L, Shen WW. 2014. Hepatotoxicity induced by clozapine: a case report and review of literature. Neuropsychiatr Dis Treat. 10:1585–1587. doi: 10.2147/NDT.S67654.
   PubMed Web of Science ®Google Scholar
• Zhang F, Han L, Wang J, Shu M, Liu K, Zhang Y, Hsiao C, Tian Q, He Q. 2021. Clozapine induced developmental and cardiac toxicity on zebrafish embryos by elevating oxidative stress. Cardiovasc Toxicol. 21(5):399–409. doi: 10.1007/s12012-021-09632-7.
   PubMed Web of Science ®Google Scholar